High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly:: an in vivo study using magnetic resonance imaging

被引:51
作者
Bogazzi, Fausto [1 ]
Lombardi, Massimo [2 ]
Strata, Elisabetta [2 ]
Aquaro, Giovanni [2 ]
Di Bello, Vitantonio [3 ]
Cosci, Chiara [1 ]
Sardella, Chiara [1 ]
Talini, Enrica [3 ]
Martino, Enio [1 ]
机构
[1] Univ Pisa, Osped Cisanello, Dept Endocrinol & Metab, I-56124 Pisa, Italy
[2] CNR, Inst Clin Physiol, Lab Magnet Resonance, Pisa, Italy
[3] Univ Pisa, Cardiothorac Dept, I-56124 Pisa, Italy
关键词
D O I
10.1111/j.1365-2265.2007.03047.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Left ventricular (LV) hypertrophy and myocardial fibrosis are considered the main pathological features of acromegalic cardiomyopathy. The aim of the study was to evaluate the proportion of LV hypertrophy and the presence of fibrosis in acromegalic cardiomyopathy in vivo using cardiac magnetic resonance (CMR). Design and patients Fourteen consecutive patients (eight women, mean age 46 +/- 10 years) with untreated active acromegaly were submitted to two-dimensional (2D) colour Doppler and integrated backscatter (IBS) echocardiography and CMR. Measurements LV volume, mass and wall thickness and myocardial tissue characterization (IBS and CMR). Results On echocardiography: mean LV mass (LVM) and LVM index (LVMi) were 209 +/- 48 g and 110 +/- 24 g/m(2), respectively; hypertrophy was revealed in five patients (36%); abnormal diastolic function [evaluated by isovolumic relaxation time (IVRT) or early (E) to late or atrial (A) peak velocities (E/A ratio)] was found in four patients (29%). Systolic function evaluated by measuring LV ejection fraction (LVEF) was normal (mean 72 +/- 12%) in all patients. Six patients (43%) had increased IBS (mean 57.4 +/- 6.2%). On CMR: mean LVM and LVMi were 151 +/- 17 g and 76 +/- 9 g/m(2), respectively; 10 patients (72%) had LV hypertrophy. Contrastographic delayed hyperenhancement was absent in all patients; on the contrary, mild enhancement was revealed in one patient. Systolic function was normal in all patients (LVEF 67 +/- 11%). LVMi was not related to serum IGF-1 concentrations or the estimated duration of disease. Conclusions CMR is considered to be the gold standard for evaluating cardiac hypertrophy, fibrosis and systolic function. Using CMR, 72% patients with untreated active acromegaly had LV hypertrophy, which was only detected in 36% patients by echocardiography. However, cardiac fibrosis was absent in all patients irrespective of the estimated duration of disease. Although a very small increase in collagen content (as suggested by increased cardiac reflectivity at IBS), not detectable by CMR, could not be ruled out, it is unlikely that it would significantly affect cardiac function.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 45 条
[1]   Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences [J].
Alfakih, K ;
Plein, S ;
Thiele, H ;
Jones, T ;
Ridgway, JP ;
Sivananthan, MU .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2003, 17 (03) :323-329
[2]   Measurement error and correlation coefficients [J].
Bland, JM ;
Altman, DG .
BRITISH MEDICAL JOURNAL, 1996, 313 (7048) :41-42
[3]   Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study [J].
Bogazzi, F ;
Di Bello, V ;
Palagi, C ;
Delle Donne, MG ;
Di Cori, A ;
Gavioli, S ;
Talini, E ;
Cosci, C ;
Sardella, C ;
Brogioni, S ;
Mariani, M ;
Martino, E .
CLINICAL ENDOCRINOLOGY, 2005, 62 (05) :590-596
[4]   Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy [J].
Choudhury, L ;
Mahrholdt, H ;
Wagner, A ;
Choi, KM ;
Elliott, MD ;
Klocke, FJ ;
Bonow, RO ;
Judd, RM ;
Kim, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) :2156-2164
[5]   Blood pressure-independent cardiac hypertrophy in acromegalic patients [J].
Ciulla, M ;
Arosio, M ;
Barelli, MV ;
Paliotti, R ;
Porretti, S ;
Valentini, P ;
Tortora, G ;
Buonamici, V ;
Moraschi, A ;
Cappiello, V ;
Magrini, F .
JOURNAL OF HYPERTENSION, 1999, 17 (12) :1965-1969
[6]   Cardiovascular function in acromegaly [J].
Clayton, RN .
ENDOCRINE REVIEWS, 2003, 24 (03) :272-277
[7]   First-line therapy of acromegaly: A statement of the ALICE (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group [J].
Colao, A. ;
Martino, E. ;
Cappabianca, P. ;
Cozzi, R. ;
Scanarini, M. ;
Ghigo, E. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2006, 29 (11) :1017-1020
[8]   Systemic complications of acromegaly: Epidemiology, pathogenesis, and management [J].
Colao, A ;
Ferone, D ;
Marzullo, P ;
Lombardi, G .
ENDOCRINE REVIEWS, 2004, 25 (01) :102-152
[9]   Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide [J].
Colao, A ;
Marzullo, P ;
Cuocolo, A ;
Spinelli, L ;
Pivonello, R ;
Bonaduce, D ;
Salvatore, M ;
Lombardi, G .
CLINICAL ENDOCRINOLOGY, 2003, 58 (02) :169-176
[10]   Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly [J].
Colao, A ;
Marzullo, P ;
Lombardi, G .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (03) :303-309